Details

Autor(en) / Beteiligte

• Ouyang, Pengwen
• Zhou, Zhijie
• Pan, Chanyuan
• Tang, Peijuan
• Long, Sheng
• Liao, Xiangjian
• Liu, Qiong
• Xie, Liangyi

Titel

Acute Exacerbation of Chronic Obstructive Pulmonary Disease Due to Carbapenem-Resistant Klebsiella pneumoniae -Induced Pneumonia: Clinical Features and Prognostic Factors

Ist Teil von

• International journal of chronic obstructive pulmonary disease, 2024-01, Vol.19, p.683-693

Ort / Verlag

New Zealand: Dove Medical Press Limited

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Carbapenem-resistant (CRKP) is closely related to respiratory tract infection. The aim of this study was to investigate the clinical features and prognostic factors of CRKP-induced pneumonia in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients. A single-centre, retrospective case-control study on COPD patients hospitalized for acute exacerbation and CRKP-induced pneumonia was conducted from January 1, 2016, to December 31, 2022. The mortality rate of acute exacerbation due to CRKP-induced pneumonia was investigated. The patients were divided into the CRKP-induced pneumonic acute exacerbation (CRKPpAE) group and the non-CRKP-induced pneumonic acute exacerbation (non-CRKPpAE) group, and the clinical characteristics and prognostic factors were compared using univariate analysis and multivariate analysis. A total of 65 AECOPD patients were included, composed of 26 patients with CRKPpAE and 39 patients with non-CRKPpAE. The mortality rate of CRKPpAE was 57.69%, while non-CRKPpAE was 7.69%. Compared with non-CRKPpAE, a history of acute exacerbation in the last year (OR=8.860, 95% CI: 1.360-57.722, =0.023), ICU admission (OR=11.736, 95% CI: 2.112-65.207, =0.005), higher NLR levels (OR=1.187, 95% CI: 1.037-1.359, =0.013) and higher D-dimer levels (OR=1.385, 95% CI: 1.006-1.905, =0.046) were independently related with CRKPpAE. CRKP isolates were all MDR strains (26/26, 100%), and MDR strains were also observed in non-CRKP isolates (5/39, 12.82%). Compared with non-CRKPpAE, CRKPpAE affects the COPD patient's condition more seriously and significantly increases the risk of death.